Lannett Adds NovoLog Biosimilar As It Writes Off $198m Of Value

Portfolio Rationalization Leads To 23 Product Discontinuations

With ambitions of $1bn of sales by 2025, Lannett is looking to bolster its top-line further by expanding its co-development pact with China’s HEC Group for insulin biosimilar products. Management discussed the goal as Lannett presented financial results, which included a significant pre-tax loss.

Syringe
Lannett has ambitions of $1bn of sales by 2025, driven by lucrative US opportunities like biosimilar insulins • Source: Shutterstock

Lannett has bolstered its biosimilar insulin co-development pact with China’s HEC Group in the US, adding a biosimilar candidate to Novo Nordisk’s NovoLog (insulin aspart) which is currently in development and for which the US-based firm will help manage the remaining clinical and regulatory steps.

The NovoLog biosimilar, which Lannett described as a “distinct product opportunity,” joins the firms’ biosimilar Lantus (insulin glargine) candidate for...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.